Ilyang Pharm Total Liabilities
Ilyang Pharm total liabilities. Based on the latest financial reports, Ilyang Pharm (007570) has total liabilities worth ₩205.41 Billion KRW (≈ $139.20 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 007570 financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Ilyang Pharm (2002–2024)
Total liabilities of Ilyang Pharm from 2002 to 2024. This chart illustrates how Ilyang Pharm's total liabilities have evolved over time, based on quarterly financial data. Explore long-term investment intensity of Ilyang Pharm to see how much of total assets are deployed in long-term investments.
Ilyang Pharm Competitors by Total Liabilities
The table below lists competitors of Ilyang Pharm ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Renascor Resources Ltd
AU:RNU
|
Australia | AU$3.83 Million |
|
KP Tissue Inc
TO:KPT
|
Canada | CA$1.80 Million |
|
BingEx Ltd
NASDAQ:FLX
|
USA | $399.94 Million |
|
Transart Graphics Co Ltd
TW:8481
|
Taiwan | NT$371.83 Million |
|
Barbeque Nation Hospitality Limited
NSE:BARBEQUE
|
India | Rs10.21 Billion |
|
Berenson Acquisition Corp I
NYSE MKT:BACA
|
USA | $27.33 Million |
|
Maronan Metals Ltd
AU:MMA
|
Australia | AU$700.14K |
|
Vow ASA
OL:VOW
|
Norway | Nkr849.80 Million |
Liability Composition Analysis (2002–2024)
This chart breaks down Ilyang Pharm's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Ilyang Pharm balance sheet assets.
Liquidity & Leverage Metrics
Ilyang Pharm Total Liabilities Ratios Explained
Ilyang Pharm total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.87 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.87 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ilyang Pharm's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ilyang Pharm (2002–2024)
The table below shows the annual total liabilities of Ilyang Pharm from 2002 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩189.63 Billion ≈ $128.51 Million |
+18.33% |
| 2023-12-31 | ₩160.25 Billion ≈ $108.60 Million |
-22.33% |
| 2022-12-31 | ₩206.33 Billion ≈ $139.83 Million |
-7.27% |
| 2021-12-31 | ₩222.51 Billion ≈ $150.79 Million |
+14.58% |
| 2020-12-31 | ₩194.19 Billion ≈ $131.60 Million |
-9.56% |
| 2019-12-31 | ₩214.72 Billion ≈ $145.51 Million |
-3.44% |
| 2018-12-31 | ₩222.37 Billion ≈ $150.70 Million |
-1.34% |
| 2017-12-31 | ₩225.39 Billion ≈ $152.74 Million |
+5.37% |
| 2016-12-31 | ₩213.91 Billion ≈ $144.96 Million |
-3.04% |
| 2015-12-31 | ₩220.62 Billion ≈ $149.51 Million |
-10.81% |
| 2014-12-31 | ₩247.37 Billion ≈ $167.64 Million |
+15.32% |
| 2013-12-31 | ₩214.50 Billion ≈ $145.37 Million |
+33.50% |
| 2009-12-31 | ₩160.67 Billion ≈ $108.89 Million |
+39.31% |
| 2004-12-31 | ₩115.33 Billion ≈ $78.16 Million |
+26.51% |
| 2003-12-31 | ₩91.16 Billion ≈ $61.78 Million |
-7.51% |
| 2002-12-31 | ₩98.56 Billion ≈ $66.80 Million |
-- |
About Ilyang Pharm
Ilyang Pharmaceutical Co.,Ltd operates as a pharmaceutical company primarily in South Korea. The company offers anticancer, circulatory system, endocrine/metabolism, cheonjiyang, female hormone, urinary system, ophthalmology, liver disease, anti-inflammatory analgesic, digestive system, dermatology, respiratory system, nutrient infusion, and neurology medicines. It also provides antibiotics, anti… Read more